Pharma R&D company scrutinizes software assets

UK-based FAST Ltd. finds in recent research that 60 percent of companies are under-licensed and 40 percent are over-licensed with their software. It cites Eisai, which manages the functions of marketing and sales, finance, medical information, market research and business operations for the pharmaceutical R&D operations of Eisai Europe and Eisai U.K., as one company that has benefited from implementing a software asset management program. Announcement

Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.